Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Uniqure stock price, quote, forecast and news

QURE
NL0010696654
A1XDTV

Price

5.47
Today +/-
+0.15
Today %
+2.97 %
P

Uniqure stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Uniqure stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Uniqure stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Uniqure stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Uniqure's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Uniqure Stock Price History

DateUniqure Price
9/11/20245.47 undefined
9/10/20245.31 undefined
9/9/20245.37 undefined
9/6/20245.42 undefined
9/5/20245.53 undefined
9/4/20245.41 undefined
9/3/20245.57 undefined
8/30/20245.85 undefined
8/29/20246.22 undefined
8/28/20246.07 undefined
8/27/20246.08 undefined
8/26/20246.12 undefined
8/23/20246.19 undefined
8/22/20246.51 undefined
8/21/20247.03 undefined
8/20/20246.78 undefined
8/19/20246.57 undefined
8/16/20246.61 undefined
8/15/20246.73 undefined
8/14/20246.70 undefined

Uniqure Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Uniqure, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Uniqure from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Uniqure’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Uniqure. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Uniqure’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Uniqure’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Uniqure’s growth potential.

Uniqure Revenue, EBIT and net profit per share

DateUniqure RevenueUniqure EBITUniqure Net Income
2029e418.44 M undefined0 undefined-52.8 M undefined
2028e274.71 M undefined-81.4 M undefined-132.52 M undefined
2027e186.15 M undefined-130.95 M undefined-182.11 M undefined
2026e112.18 M undefined-126.28 M undefined-113.48 M undefined
2025e69.21 M undefined-148.15 M undefined-138.19 M undefined
2024e45.56 M undefined-190.37 M undefined-211.16 M undefined
202315.84 M undefined-282.87 M undefined-308.48 M undefined
2022106.5 M undefined-143.2 M undefined-126.8 M undefined
2021524 M undefined310.6 M undefined329.6 M undefined
202037.5 M undefined-125.4 M undefined-125 M undefined
20197.3 M undefined-121.1 M undefined-124.2 M undefined
201811.3 M undefined-88.2 M undefined-83.3 M undefined
201713.1 M undefined-71.3 M undefined-79.3 M undefined
201625.1 M undefined-71.9 M undefined-73.4 M undefined
201510.6 M undefined-71.2 M undefined-82.1 M undefined
20146.1 M undefined-53.7 M undefined-49.8 M undefined
20133.9 M undefined-29.9 M undefined-35.6 M undefined
20120 undefined-18.2 M undefined-18.9 M undefined
20110 undefined-23.8 M undefined-24.1 M undefined

Uniqure Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
003610251311737524106154569112186274418
---100.0066.67150.00-48.00-15.38-36.36428.571,316.22-79.77-85.85200.0053.3362.3266.0747.3152.55
--66.67-------95.2397.1713.33------
00200000004991032000000
-23-18-29-53-71-71-71-88-121-125310-143-282-190-148-126-130-810
---966.67-883.33-710.00-284.00-546.15-800.00-1,728.57-337.8459.16-134.91-1,880.00-422.22-214.49-112.50-69.89-29.56-
-24-18-35-49-82-73-79-83-124-125329-126-308-211-138-113-182-132-52
--25.0094.4440.0067.35-10.988.225.0649.400.81-363.20-138.30144.44-31.49-34.60-18.1261.06-27.47-60.61
16.816.810.817.122.1252735.64044.546.846.747.67000000
-------------------
Details

Keystats

ⓘ

Revenue and Growth

The Uniqure Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Uniqure is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2011201220132014201520162017201820192020202120222023
                         
1.40.332.764.4221.6132.5159.4234.9377.8244.9556.3352.8617.89
00004.19.21.60.20.96.658.8102.44.19
01.100000000000
001.20.20.50000006.912.02
000.50.61.92.31.81.45.47.313.214.617.74
1.41.434.465.2228.1144162.8236.5384.1258.8628.3476.7651.85
1.21.63.623.82635.734.329.255.658.469.183.375.34
00000000000400
0000000000000
3.54.310.719.86.88.39.65.25.43.462.758.860.48
0001.60.50.50.50.50.50.527.625.626.38
001.31.21.21.82.52.42.919.221.520.617.64
4.75.915.646.434.546.346.937.364.481.5180.9228.3179.84
6.17.350111.6262.6190.3209.7273.8448.5340.3809.2705831.69
                         
0.30.60.81.11.51.61.92.32.72.72.82.82.88
0.130.150.20.250.460.460.570.720.991.021.081.111.15
-133-152.7-189-198.3-322.7-396.1-475.3-535.5-659.7-784.7-455.1-581.9-890.41
0000-6.8-6.6-3.8-7.3-6.79.9-28.9-58.3-53.55
0000000000000
-3.3-0.67.652.1127.963.689.3179.6323.1243.9595.8476207.67
2.22.810.45.94.15.52.93.85.73.82.5116.59
0001.29.99.887.718.321.534.33938.88
2.52.837.87.46.87.38.57.62.102628.21
01.800000000000
000.905.60.61.1000000
4.77.414.314.92722.719.32031.627.436.87673.68
6.109.12014.619.619.735.536.135.6101102.8495.99
0001.700000012.98.37.54
00.622.527.293.284.381.338.957.933.562.84246.81
6.10.631.648.9107.8103.910174.49469.1176.7153.1550.34
10.8845.963.8134.8126.6120.394.4125.696.5213.5229.1624.02
7.57.453.5115.9262.7190.2209.6274448.7340.4809.3705.1831.69
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Uniqure provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Uniqure's financial health and stability.

Assets

Uniqure's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Uniqure must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Uniqure after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Uniqure's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2011201220132014201520162017201820192020202120222023
-24-18-35-49-82-73-79-83-124-125329-126-308
0002667126107811
0000-11000-163-11
-1021065-10-14-6-2-40-50-4381
2510183010321138572352102
00112212346916
0000000000000
-23-14-5-367-72-64-76-98-134288-145-145
0-1-8-22-8-17-5-4-6-9-17-17-7
0-1-7-23-8-17-5-4-6-9-67-182-205
000-1000000-49-165-198
0000000000000
012590001400620374
0008516029014324873310
01444941602901582487941362
012190000000-10-11
0000000000000
-23-13131157-882775143-133311-32813
-23.6-15.7-13.5-59.4-0.5-89.4-69.9-80.2-105.3-144.3270.6-162.8-153.08
0000000000000

Uniqure stock margins

The Uniqure margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Uniqure. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Uniqure.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Uniqure's sales revenue. A higher gross margin percentage indicates that the Uniqure retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Uniqure's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Uniqure's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Uniqure's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Uniqure. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Uniqure's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Uniqure Margin History

Uniqure Gross marginUniqure Profit marginUniqure EBIT marginUniqure Profit margin
2029e13.98 %0 %-12.62 %
2028e13.98 %-29.63 %-48.24 %
2027e13.98 %-70.35 %-97.83 %
2026e13.98 %-112.57 %-101.16 %
2025e13.98 %-214.06 %-199.67 %
2024e13.98 %-417.82 %-463.45 %
202313.98 %-1,785.46 %-1,947.09 %
202296.81 %-134.46 %-119.06 %
202195.23 %59.27 %62.9 %
202013.98 %-334.4 %-333.33 %
201913.98 %-1,658.9 %-1,701.37 %
201813.98 %-780.53 %-737.17 %
201713.98 %-544.27 %-605.34 %
201613.98 %-286.45 %-292.43 %
201513.98 %-671.7 %-774.53 %
201413.98 %-880.33 %-816.39 %
201371.79 %-766.67 %-912.82 %
201213.98 %0 %0 %
201113.98 %0 %0 %

Uniqure Stock Sales Revenue, EBIT, Earnings per Share

The Uniqure earnings per share therefore indicates how much revenue Uniqure has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Uniqure earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Uniqure's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Uniqure’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Uniqure's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Uniqure Revenue, EBIT and net profit per share

DateUniqure Sales per ShareUniqure EBIT per shareUniqure Earnings per Share
2029e8.59 undefined0 undefined-1.08 undefined
2028e5.64 undefined0 undefined-2.72 undefined
2027e3.82 undefined0 undefined-3.74 undefined
2026e2.3 undefined0 undefined-2.33 undefined
2025e1.42 undefined0 undefined-2.84 undefined
2024e0.94 undefined0 undefined-4.34 undefined
20230.33 undefined-5.93 undefined-6.47 undefined
20222.28 undefined-3.07 undefined-2.72 undefined
202111.2 undefined6.64 undefined7.04 undefined
20200.84 undefined-2.82 undefined-2.81 undefined
20190.18 undefined-3.03 undefined-3.11 undefined
20180.32 undefined-2.48 undefined-2.34 undefined
20170.49 undefined-2.64 undefined-2.94 undefined
20161 undefined-2.88 undefined-2.94 undefined
20150.48 undefined-3.22 undefined-3.71 undefined
20140.36 undefined-3.14 undefined-2.91 undefined
20130.36 undefined-2.77 undefined-3.3 undefined
20120 undefined-1.08 undefined-1.13 undefined
20110 undefined-1.42 undefined-1.43 undefined

Uniqure business model

Uniqure NV is a Dutch biotechnology company specializing in the development of gene therapies for rare diseases. The company was founded in 1999 and is headquartered in Amsterdam. Uniqure is one of the most popular companies on Eulerpool.com.

Uniqure SWOT Analysis

Strengths

Uniqure NV has several strengths that contribute to its competitive advantage in the market:

  • 1. Advanced Gene Therapy Technology: Uniqure NV possesses cutting-edge gene therapy technology, allowing them to develop innovative treatments for genetic diseases.
  • 2. Strong Research and Development Capabilities: The company has a dedicated team of researchers and scientists who continuously work on developing new gene therapies.
  • 3. Extensive Intellectual Property Portfolio: Uniqure NV has a significant number of patents and trademarks protecting its gene therapy technologies and products.
  • 4. Strategic Partnerships: The company has established partnerships with leading pharmaceutical companies, enabling them to access resources, expertise, and distribution channels.

Weaknesses

Despite its strengths, Uniqure NV also faces certain weaknesses that could hinder its growth and success:

  • 1. Limited Product Portfolio: The company currently focuses on a narrow range of gene therapy products, limiting their revenue streams and market reach.
  • 2. Regulatory Challenges: The gene therapy industry faces strict regulations and approvals, which can result in delays and increased costs for product development and commercialization.
  • 3. Financial Dependence: Uniqure NV heavily relies on external funding and partnerships to support its research, development, and marketing efforts.
  • 4. Vulnerability to Competition: As the gene therapy market evolves rapidly, Uniqure NV faces competition from established pharmaceutical companies and emerging biotech startups.

Opportunities

Uniqure NV can leverage various opportunities to expand its market presence and generate growth:

  • 1. Growing Demand for Gene Therapies: The increasing prevalence of genetic diseases and advancements in gene therapy research present a significant market opportunity.
  • 2. Expansion into New Geographies: Uniqure NV can explore untapped markets and international expansion to reach a broader patient population.
  • 3. Strategic Collaborations: Forming alliances with healthcare organizations, research institutions, and biotech companies can enhance Uniqure NV's research capabilities and market reach.
  • 4. Themedical Technologies Partnership: Collaborating with other companies in the medical technology sector can help Uniqure NV diversify its product portfolio and unlock synergies.

Threats

Uniqure NV faces certain threats that could impact its business operations and market position:

  • 1. Regulatory Risks: The gene therapy industry is subject to evolving regulations, and changes in policies or safety concerns may impact the approval and commercialization of Uniqure NV's products.
  • 2. Competitive Landscape: The gene therapy market is becoming increasingly competitive, with the entry of new players and established companies investing in gene therapy research and development.
  • 3. Intellectual Property Challenges: Uniqure NV's patents and trademarks may face legal challenges or infringements, potentially impacting their exclusivity and marketability.
  • 4. Market Volatility: Economic uncertainties, market fluctuations, and shifts in healthcare policies can influence the demand for gene therapies and financial stability.

Uniqure Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Uniqure historical P/E ratio, EBIT, and P/S ratio.

Uniqure shares outstanding

The number of shares was Uniqure in 2023 — This indicates how many shares 47.671 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Uniqure earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Uniqure's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Uniqure’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Uniqure's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Uniqure.

Uniqure latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-1.28 -1.16  (9.38 %)2024 Q2
3/31/2024-1.31 -1.36  (-4.17 %)2024 Q1
12/31/2023-1.48 -1.53  (-3.13 %)2023 Q4
9/30/2023-0.87 -1.88  (-117.04 %)2023 Q3
6/30/20232.09 -1.44  (-168.86 %)2023 Q2
3/31/2023-0.97 -1.63  (-68.68 %)2023 Q1
12/31/2022-0.9 0.15  (116.06 %)2022 Q4
9/30/2022-1.18 -1.02  (13.46 %)2022 Q3
6/30/2022-1.02 -0.84  (17.29 %)2022 Q2
3/31/2022-0.95 -1  (-5.04 %)2022 Q1
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Uniqure stock

Eulerpool World ESG Rating (EESG©)

60/ 100

🌱 Environment

55

👫 Social

91

🏛️ Governance

33

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees54
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Uniqure list of shareholders

%
Name
Stocks
Change
Date
8.05955 % Vestal Point Capital, LP3,925,0003,925,00012/31/2023
7.14347 % State Street Global Advisors (US)3,478,87228,59012/31/2023
6.07398 % Nantahala Capital Management, LLC2,958,027-65,77212/31/2023
4.90371 % Bristol Myers Squibb2,388,10809/15/2023
3.47639 % 683 Capital Management LLC1,693,000118,00012/31/2023
3.00161 % BlackRock Institutional Trust Company, N.A.1,461,782206,01212/31/2023
2.76776 % OrbiMed Advisors, LLC1,347,900-716,55512/31/2023
2.71919 % Pictet Asset Management Ltd.1,324,246320,55212/31/2023
2.54928 % Schroder Investment Management Ltd. (SIM)1,241,5001,241,50012/31/2023
2.54928 % International Biotechnology Trust PLC1,241,5001,226,0009/30/2023
1
2
3
4
5
...
10

Uniqure Executives and Management Board

Mr. Matthew Kapusta50
Uniqure Chief Executive Officer, Executive Director (since 2015)
Compensation 5.63 M
Dr. Ricardo Dolmetsch54
Uniqure Chief Business and Scientific Officer
Compensation 2.89 M
Mr. Pierre Caloz51
Uniqure Chief Operations Officer
Compensation 2.37 M
Mr. Christian Klemt50
Uniqure Chief Financial Officer
Compensation 2.13 M
Ms. Maria Cantor
Uniqure Chief Corporate Affairs Officer (since 2022)
Compensation 1.22 M
1
2
3

Uniqure Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
CSL Stock
CSL
SupplierCustomer0,66-0,15-0,340,700,820,42
REGENXBIO Stock
REGENXBIO
SupplierCustomer0,590,930,890,660,820,55
Bristol-Myers Squibb Stock
Bristol-Myers Squibb
SupplierCustomer0,27-0,32-0,10-0,72-0,64-0,63
4D Molecular Therapeutics Stock
4D Molecular Therapeutics
SupplierCustomer0,180,820,750,850,91-
Sanofi Stock
Sanofi
SupplierCustomer-0,050,41-0,14-0,65-0,78-0,69
1

Most common questions regarding Uniqure

What values and corporate philosophy does Uniqure represent?

Uniqure NV represents values of pioneering gene therapies and a commitment to transforming the lives of patients with severe genetic diseases. The company's corporate philosophy is centered around innovation, scientific excellence, and patient-centricity. Uniqure NV is dedicated to developing and delivering breakthrough treatments utilizing its proprietary gene therapy platform, focusing on addressing unmet medical needs. With a strong emphasis on collaboration and partnerships, Uniqure NV strives to advance the field of gene therapy, offering hope and improved quality of life to individuals affected by rare genetic disorders.

In which countries and regions is Uniqure primarily present?

Uniqure NV is primarily present in various countries and regions across the globe. Some key locations where the company has a significant presence include the United States, Europe, and Canada. With its headquarters in the Netherlands, Uniqure NV has a strong foothold in Europe, particularly in countries like Germany, France, and the United Kingdom. Additionally, the company has expanded its reach to North America, with operations in the United States and Canada. Uniqure NV's global presence allows it to engage with a diverse range of markets and customers, facilitating its growth and impact in the field of genetic therapies.

What significant milestones has the company Uniqure achieved?

Uniqure NV, a leading biopharmaceutical company, has achieved several significant milestones. It pioneered gene therapy and became the first company to gain approval for a gene therapy product in the European Union. Furthermore, Uniqure NV successfully launched Glybera, a groundbreaking treatment for patients with lipoprotein lipase deficiency. The company also forged strategic collaborations with top pharmaceutical companies to advance gene therapies for various diseases. Uniqure NV's dedication to innovation and its groundbreaking achievements have positioned the company as a pioneering force in the field of gene therapy, driving advancements in healthcare and offering hope for patients worldwide.

What is the history and background of the company Uniqure?

Uniqure NV is a pioneering gene therapy company that has made significant contributions in the field of genetic medicine. Founded in 1999, Uniqure NV has been dedicated to developing innovative treatments for rare genetic diseases and has successfully brought several therapies to market. With a focus on gene therapy platforms, the company has demonstrated its expertise in delivering long-lasting therapeutic effects. Uniqure NV has collaborated with leading research institutes and pharmaceutical companies to advance the field of gene therapy. Its commitment to improving patient outcomes through groundbreaking therapies has earned Uniqure NV a prominent position in the biotechnology industry.

Who are the main competitors of Uniqure in the market?

The main competitors of Uniqure NV in the market are established companies such as Pfizer and Novartis. These pharmaceutical giants also specialize in gene therapy and have a significant presence in the biotechnology industry. Uniqure NV, a pioneering company in gene therapy, competes with these industry leaders in the development and commercialization of innovative treatments for genetic disorders. Their expertise and advancements in gene therapy contribute to the company's growth and sustenance in a fiercely competitive market.

In which industries is Uniqure primarily active?

Uniqure NV is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Uniqure?

The business model of Uniqure NV focuses on developing and commercializing innovative gene therapies to treat severe genetic diseases. Uniqure NV utilizes its proprietary technology platform to create gene therapies that have the potential to provide long-lasting benefits. By using a targeted approach, Uniqure NV aims to address the underlying cause of genetic diseases, offering potential cures rather than simply managing symptoms. The company collaborates with academic institutions, pharmaceutical companies, and healthcare organizations to advance its research and development efforts. Uniqure NV's business model revolves around the development, manufacturing, and commercialization of gene therapies to improve the lives of patients affected by genetic disorders.

What is the P/E ratio of Uniqure 2024?

The Uniqure P/E ratio is -1.23.

What is the P/S ratio of Uniqure 2024?

The Uniqure P/S ratio is 5.72.

What is the AlleAktien quality score of Uniqure?

The AlleAktien quality score for Uniqure is 5/10.

What is the revenue of Uniqure 2024?

The expected Uniqure revenue is 45.56 M USD.

How high is the profit of Uniqure 2024?

The expected Uniqure profit is -211.16 M USD.

What is the business model of Uniqure

Uniqure NV is a leading biotechnology company specializing in the development of innovative gene therapies for genetic diseases. The company utilizes its proprietary gene therapy platform to develop life-changing therapies for patients in various therapeutic areas. The business model of Uniqure is based on collaboration with leading academics and companies in the biotech industry, as well as its own research and development strategy. The company has a variety of partnerships with pharmaceutical and biotech companies to expand its portfolio of gene therapy products and bring them to market. Uniqure is one of the few companies using gene editing technology to treat genetic diseases. This technology allows for the correction or replacement of specific genes in human cells. This is a breakthrough in gene therapy, as previous approaches often only provided symptomatic treatment. Uniqure's product portfolio currently includes a wide range of gene therapy products in various stages of clinical development and therapeutic areas. Some of these therapies are already in phase III clinical trials, focusing on diseases such as hemophilia, Huntington's disease, and spinal muscular atrophy. Uniqure also focuses on developing gene therapies for rare diseases that have been previously unmet medical needs. These niche markets offer enormous opportunities for the company, as they are often overlooked by other companies due to their low potential. The business model of Uniqure also includes a strong patent and technology protection strategy to ensure long-term competitiveness. The company places a strong emphasis on regulatory compliance and collaboration with regulatory authorities to facilitate the approval of its treatment products. The company has a variety of financing options, including venture capital and public financing. Uniqure also has a strong partnership with multinational pharmaceutical companies such as Bristol-Myers Squibb, who support the company in bringing its gene therapy products to the global market. Overall, the business model of Uniqure NV offers a wide range of innovative gene therapies for the treatment of genetic diseases, as well as a strong protection strategy for its technologies and patents. With strong partnerships and a broad research and development strategy, the company offers enormous opportunities for growth in the coming years.

What is the Uniqure dividend?

Uniqure pays a dividend of 0 USD distributed over payouts per year.

How often does Uniqure pay dividends?

The dividend cannot currently be calculated for Uniqure or the company does not pay out a dividend.

What is the Uniqure ISIN?

The ISIN of Uniqure is NL0010696654.

What is the Uniqure WKN?

The WKN of Uniqure is A1XDTV.

What is the Uniqure ticker?

The ticker of Uniqure is QURE.

How much dividend does Uniqure pay?

Over the past 12 months, Uniqure paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Uniqure is expected to pay a dividend of 0 USD.

What is the dividend yield of Uniqure?

The current dividend yield of Uniqure is .

When does Uniqure pay dividends?

Uniqure pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Uniqure?

Uniqure paid dividends every year for the past 0 years.

What is the dividend of Uniqure?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Uniqure located?

Uniqure is assigned to the 'Health' sector.

Wann musste ich die Aktien von Uniqure kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Uniqure from 9/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/12/2024.

When did Uniqure pay the last dividend?

The last dividend was paid out on 9/12/2024.

What was the dividend of Uniqure in the year 2023?

In the year 2023, Uniqure distributed 0 USD as dividends.

In which currency does Uniqure pay out the dividend?

The dividends of Uniqure are distributed in USD.

All fundamentals about Uniqure

Our stock analysis for Uniqure Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Uniqure Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.